Goodwin Procter acted for Deep Apple Therapeutics in a research collaboration and exclusive worldwide license agreement with Novo Nordisk to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases.